CollPlant Biotechnologies Ltd. filings document foreign private issuer current reports for a regenerative and aesthetic medicine company built around plant-derived rhCollagen. Form 6-K reports cover operating and financial results, corporate updates on BioInk, Collink.3D, BioFlex, Vergenix STR and photocurable dermal filler technology, as well as intellectual-property disclosures and collaboration-related material events.
The filing record also documents capital-structure matters involving ordinary shares and warrants, Nasdaq Capital Market bid-price compliance notices, and material agreements. Certain 6-K reports are incorporated by reference into the company’s Form S-8 and Form F-3 registration statements, linking current-event disclosures to equity compensation and shelf-registration records.
CollPlant Biotechnologies Ltd. (CLGN) reports that it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2), which calls for a minimum bid of $1.00 per share. Nasdaq confirmed that CollPlant’s ordinary shares closed at or above $1.00 for ten consecutive business days from September 4 to September 18, 2026, formally closing the prior deficiency matter that began with a notice on March 23, 2026. Management emphasizes the importance of maintaining the Nasdaq listing and links this milestone to its broader strategy, including the recently completed LightSolver acquisition in high-performance computing and continued development of its rhCollagen regenerative medicine platform.
CollPlant Biotechnologies Ltd. (CLGN) furnished an updated corporate presentation highlighting its LightSolver acquisition and strategy to enter high-performance computing (HPC). The presentation positions LightSolver’s all-optical “Laser Processing Unit” (LPU) as a future computing platform targeting optimization and simulation workloads in large HPC markets.
The materials describe a transaction structure in which CollPlant provides a public-company platform and resources, including $5 million of funding to LightSolver at closing, plus closing shares and pre-funded warrants and additional warrant tranches tied to specified technology and commercial milestones. CollPlant states it continues to evaluate strategic alternatives for its existing biotech assets with the objective of maximizing shareholder value.
CollPlant Biotechnologies Ltd (symbol: CLGN) is the issuer of record for a Form 4 filing submitted to the SEC. Rotem Eran reported acquisition or exercise transactions in this Form 4 filing.
CollPlant Biotechnologies Ltd (CLGN) reported that Deputy CEO and CFO Rotem Eran received a grant of 510,372 restricted share units (RSUs) on September 3, 2026, each RSU representing a contingent right to one ordinary share. 30% of these RSUs vest on September 3, 2027, and the remaining 70% vest in equal installments every three months over the following four years, with full vesting on September 3, 2031, subject to continued service. After this grant and giving effect to the issuer’s 1-for-10 reverse stock split effective September 4, 2026, Eran’s reported holdings total 516,372 ordinary-share equivalents, including newly awarded and previously held RSUs and shares.
CollPlant Biotechnologies Ltd (symbol: CLGN) is the issuer of record for a Form 4 filing submitted to the SEC. Abelis Bar Berta reported acquisition or exercise transactions in this Form 4 filing.
CollPlant Biotechnologies Ltd (CLGN) reported that its VP Legal, Abelis Bar Berta, received a grant of 201,141 restricted share units (RSUs) on September 3, 2026. Thirty percent of the RSUs vest on September 3, 2027, with the remaining 70% vesting quarterly over four years through September 3, 2031, subject to continued service. After this award, the reporting person holds 206,441 ordinary-share interests, including shares and RSUs. A 1-for-10 reverse stock split effective September 4, 2026 is reflected in the reported amounts, and no Rule 10b5-1 trading plan is indicated.
CollPlant Biotechnologies Ltd. (CLGN) reports that Dr. Ruti Ben Shlomi, Chief Executive Officer and Co-Founder of LightSolver Ltd., has been appointed to CollPlant’s Board of Directors, effective immediately following the completion of CollPlant’s acquisition of LightSolver, as announced on September 3, 2026.
The company explains that LightSolver develops pure photonic, laser-based high-performance computing technology using its proprietary Laser Processing Unit (LPU) to accelerate complex computational workloads. CollPlant describes this acquisition as expanding its activities beyond regenerative medicine into advanced high-performance and photonic computing, while it continues to focus on 3D bioprinting, tissue repair and medical aesthetics.
CollPlant Biotechnologies Ltd. (CLGN) completed the acquisition of LightSolver Ltd. on September 3, 2026 under a Share Purchase Agreement dated August 29, 2026. The transaction used an equity-centric structure, including upfront ordinary shares, pre-funded warrants and a $5 million investment in LightSolver, with additional milestone-based warrants tied to specified technological and commercial achievements.
Through this deal, CollPlant formally enters the high-performance computing and photonics sectors while continuing its regenerative medicine activities. LightSolver contributes its Laser Processing Unit all-optical computing architecture, aimed at accelerating demanding workloads across areas such as aerospace, defense, advanced engineering, financial services and Physical AI.
CollPlant Biotechnologies Ltd. (CLGN) is implementing a 1-for-10 reverse share split of its ordinary shares, so every ten existing shares will be consolidated into one share. The reverse split will take effect when the Nasdaq Capital Market opens on September 4, 2026, after which the shares will trade on a split-adjusted basis under the same ticker.
The Board of Directors approved the reverse split following shareholder approval at an Extraordinary General Meeting on August 18, 2026, as part of a strategic plan to help regain compliance with the Nasdaq minimum bid price requirement for continued listing. No fractional shares will be issued; fractions will be rounded to the nearest whole share. Exercise prices and share amounts under all outstanding options and warrants will be adjusted proportionately, and the ordinary shares will trade under a new CUSIP number, M2R51X124.
Shareholders holding in book-entry or through banks or brokers do not need to take action, while holders of physical certificates will receive instructions from transfer agent Computershare Inc. The company also notes a recent definitive agreement to acquire LightSolver Ltd., an Israeli deep-tech computing company.
CollPlant Biotechnologies Ltd (symbol: CLGN) is the issuer of record for a Form 6-K filing submitted to the SEC.
CollPlant Biotechnologies Ltd (CLGN) received a significant investment from The Loewenbaum 1992 Trust, which on June 29, 2026 agreed to purchase 1,764,706 Ordinary Shares, Series A Warrants to buy 1,764,706 shares and Series B Warrants to buy 3,529,412 shares at an exercise price of $0.34 per share. The transaction closed on July 6, 2026, with the Series A and B Warrants becoming exercisable following shareholder approval on July 29, 2026, and expiring in 2028 and 2031, respectively.
As of August 19, 2026, CollPlant had 18,908,207 Ordinary Shares outstanding. For ownership calculations, 20,570,548 shares are assumed outstanding, including up to approximately 1,662,341 shares issuable upon warrant exercise subject to a 24.99% Beneficial Ownership Limitation. Collectively, the Loewenbaum-related reporting persons beneficially own 5,140,580 Ordinary Shares, representing 24.99% of this adjusted total. The group states the holdings are for investment purposes and that they currently have no specific plans for corporate actions beyond what is described.
CollPlant Biotechnologies Ltd. (CLGN) reports that it held an Extraordinary General Meeting of Shareholders on August 18, 2026. Shareholders approved both proposals presented at the meeting, each receiving the required majority as outlined in the previously distributed meeting notice.
The report is also incorporated by reference into the company’s existing Form S-8 and Form F-3 registration statements, meaning the meeting outcome and related disclosures become part of those registration frameworks.